Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Crizotinib

FDA-approved product (capsule, oral), marketed as Xalkori.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Crizotinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Crizotinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Crizotinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

    NCT07804186 · start 2026-09

    Registered record
    Registry ID
    NCT07804186
    Conditions
    Uveal Melanoma
    Interventions
    Darovasertib; Crizotinib (Xalkori)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-09
    Completion
    2034-04
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUveal Melanoma
    InterventionDarovasertib; Crizotinib (Xalkori)
    PhasePhase 3
    Registry statusRecruiting

  • Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

    NCT06563999 · start 2024-11-01

    Registered record
    Registry ID
    NCT06563999
    Conditions
    Lung Cancer Stage III; Mutation
    Interventions
    Sunvozertinib; Crizotinib; Pralsetinib; Larotrectinib; Savolitinib; Pyrotinib; Dabrafenib+Trametinib; Glecirasib; Ensartinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-11-01
    Completion
    2029-11-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer Stage III; Mutation
    InterventionSunvozertinib; Crizotinib; Pralsetinib; Larotrectinib +5 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

    NCT05297890 · start 2022-05-27

    Registered record
    Registry ID
    NCT05297890
    Conditions
    Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
    Interventions
    Lorlatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-05-27
    Completion
    2027-05
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
    InterventionLorlatinib
    PhasePhase 2
    Registry statusActive not recruiting

  • Personalized DC Vaccines in Non Small Cell Lung Cancer

    NCT05195619 · start 2022-03-22

    Registered record
    Registry ID
    NCT05195619
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine); Low dose cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2022-03-22
    Completion
    2027-06
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionAutologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine); Low dose cyclophosphamide
    PhasePhase 1
    Registry statusActive not recruiting

  • Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC

    NCT06569420 · start 2021-12-31

    Registered record
    Registry ID
    NCT06569420
    Conditions
    Non-Small Cell Lung Cancer; ALK-positive; SAF-189s
    Interventions
    Drug: Foritinib Succinate; Drug: Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-12-31
    Completion
    2027-12-31
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer; ALK-positive; SAF-189s
    InterventionDrug: Foritinib Succinate; Drug: Crizotinib
    PhasePhase 3
    Registry statusActive not recruiting

  • Antineoplastic Drugs in Elderly Patients

    NCT05467189 · start 2021-01-01

    Registered record
    Registry ID
    NCT05467189
    Conditions
    Cancer
    Interventions
    Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-01-01
    Completion
    2028-06-30
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionBusulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)
    PhaseNot recorded
    Registry statusRecruiting

  • Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

    NCT04211922 · start 2020-01-21

    Registered record
    Registry ID
    NCT04211922
    Conditions
    ALK-positive Non-small Cell Lung Cancer
    Interventions
    Alkotinib Capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-01-21
    Completion
    2022-10-11
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK-positive Non-small Cell Lung Cancer
    InterventionAlkotinib Capsules
    PhasePhase 2
    Registry statusTerminated

  • Study of Crizotinib for ROS1 and MET Activated Lung Cancer

    NCT04084717 · start 2019-12-03

    Registered record
    Registry ID
    NCT04084717
    Conditions
    Non-squamous Non-small-cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; ROS1 Gene Rearrangement; MET Activating Mutation; MET Amplification
    Interventions
    Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-12-03
    Completion
    2024-12-30
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-squamous Non-small-cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; ROS1 Gene Rearrangement; MET Activating Mutation +1 more
    InterventionCrizotinib
    PhasePhase 2
    Registry statusCompleted

  • Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

    NCT03737994 · start 2019-07-25

    Registered record
    Registry ID
    NCT03737994
    Conditions
    Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
    Interventions
    Alectinib; Brigatinib; Carboplatin; Ceritinib; Cisplatin; Crizotinib; Ensartinib; Lorlatinib; Pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-07-25
    Completion
    2026-03-17
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
    InterventionAlectinib; Brigatinib; Carboplatin; Ceritinib +5 more
    PhasePhase 2
    Registry statusTerminated

  • Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors

    NCT03874273 · start 2019-02-01

    Registered record
    Registry ID
    NCT03874273
    Conditions
    Inflammatory Myofibroblastic Tumor
    Interventions
    Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2019-02-01
    Completion
    2021-03-01
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammatory Myofibroblastic Tumor
    InterventionCrizotinib
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

    NCT03215693 · start 2017-09-28

    Registered record
    Registry ID
    NCT03215693
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    X-396 capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2017-09-28
    Completion
    2023-12
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionX-396 capsule
    PhasePhase 2
    Registry statusUnknown

  • A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.

    NCT03137134 · start 2017-06-20

    Registered record
    Registry ID
    NCT03137134
    Conditions
    Healthy
    Interventions
    Crizotinib; Esomeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-06-20
    Completion
    2017-10-17
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCrizotinib; Esomeprazole
    PhasePhase 1
    Registry statusCompleted

  • A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

    NCT03052608 · start 2017-04-27

    Registered record
    Registry ID
    NCT03052608
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Lorlatinib; Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2017-04-27
    Completion
    2028-12-31
    Enrolment
    296

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionLorlatinib; Crizotinib
    PhasePhase 3
    Registry statusActive not recruiting

  • Descriptive Observational Study ALK-2016-CPHG

    NCT03718117 · start 2017-01-03

    Registered record
    Registry ID
    NCT03718117
    Conditions
    NSCLC; Crizotinib; ALK Gene Rearrangement or ROS1 Gene Rearrangement
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-01-03
    Completion
    2020-07-01
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC; Crizotinib; ALK Gene Rearrangement or ROS1 Gene Rearrangement
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

    NCT02838420 · start 2016-08-03

    Registered record
    Registry ID
    NCT02838420
    Conditions
    Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
    Interventions
    Alectinib; Crizotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-08-03
    Completion
    2026-05-11
    Enrolment
    187

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
    InterventionAlectinib; Crizotinib
    PhasePhase 3
    Registry statusCompleted